Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October

Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in October. Read more >>